Zentiva AG, a wholly-owned subsidiary of Zentiva Pharma GmbH, headquartered in Frankfurt am Main, Germany, and part of Zentiva group has announced that it has secured approx. 83.57% of the share capital and approx. 85.27% of voting rights in the context of its voluntary public purchase offer for Apontis Pharma following the end of the acceptance period on 21 November 2024.
Steffen Saltofte, CEO of Zentiva, said, “We are pleased with the success of our public purchase offer. This milestone marks a significant step forward in our journey to expand our reach and enhance our ability to deliver high-quality, affordable medicines to the people who depend on them every day. We look forward to combining our strengths and working together under a unified ownership structure to deliver on our long-term strategy.”
Settlement of the offer is still subject to foreign direct investment control clearance in Germany. Settlement is expected to occur in December 2024 or in Q1 2025.
Zentiva is a Pan-European Platform developing, manufacturing and providing high-quality and affordable medicines to more than 100 million people in Europe. Zentiva has four wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. It offers solutions in key therapeutic areas such as cardiology & circulation, diabetes, oncology, respiratory, CNS and focuses on expanding our portfolio in self-care. Apontis Pharma is a leading pharmaceutical company specializing in Single Pill combinations in Germany.
